328 related articles for article (PubMed ID: 22136820)
1. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer.
Popadich A; Levin O; Lee JC; Smooke-Praw S; Ro K; Fazel M; Arora A; Tolley NS; Palazzo F; Learoyd DL; Sidhu S; Delbridge L; Sywak M; Yeh MW
Surgery; 2011 Dec; 150(6):1048-57. PubMed ID: 22136820
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications.
So YK; Seo MY; Son YI
Surgery; 2012 Feb; 151(2):192-8. PubMed ID: 21497873
[TBL] [Abstract][Full Text] [Related]
3. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.
Laird AM; Gauger PG; Miller BS; Doherty GM
World J Surg; 2012 Jun; 36(6):1268-73. PubMed ID: 22270997
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
6. Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?
Alvarado R; Sywak MS; Delbridge L; Sidhu SB
Surgery; 2009 May; 145(5):514-8. PubMed ID: 19375610
[TBL] [Abstract][Full Text] [Related]
7. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
8. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center.
Dobrinja C; Troian M; Cipolat Mis T; Rebez G; Bernardi S; Fabris B; Piscopello L; Makovac P; Di Gregorio F; de Manzini N
Int J Surg; 2017 May; 41 Suppl 1():S40-S47. PubMed ID: 28506412
[TBL] [Abstract][Full Text] [Related]
9. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.
Hughes DT; White ML; Miller BS; Gauger PG; Burney RE; Doherty GM
Surgery; 2010 Dec; 148(6):1100-6; discussion 1006-7. PubMed ID: 21134539
[TBL] [Abstract][Full Text] [Related]
10. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
11. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
12. Level VI lymph node dissection for papillary thyroid cancer.
White ML; Doherty GM
Minerva Chir; 2007 Oct; 62(5):383-93. PubMed ID: 17947949
[TBL] [Abstract][Full Text] [Related]
13. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients.
Gambardella C; Tartaglia E; Nunziata A; Izzo G; Siciliano G; Cavallo F; Mauriello C; Napolitano S; Thomas G; Testa D; Rossetti G; Sanguinetti A; Avenia N; Conzo G
World J Surg Oncol; 2016 Sep; 14(1):247. PubMed ID: 27644091
[TBL] [Abstract][Full Text] [Related]
15. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
16. Reoperative central lymph node dissection for incidental papillary thyroid cancer can be performed safely: A retrospective review.
Hall CM; LaSeur DC; Snyder SK; Lairmore TC
Int J Surg; 2018 Aug; 56():102-107. PubMed ID: 29920338
[TBL] [Abstract][Full Text] [Related]
17. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence.
Hall CM; Snyder SK; Maldonado YM; Lairmore TC
Surgery; 2016 Oct; 160(4):1049-1058. PubMed ID: 27521047
[TBL] [Abstract][Full Text] [Related]
18. Central lymph node dissection in differentiated thyroid cancer.
White ML; Gauger PG; Doherty GM
World J Surg; 2007 May; 31(5):895-904. PubMed ID: 17347896
[TBL] [Abstract][Full Text] [Related]
19. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
20. The clinical prognosis of patients with cN0 papillary thyroid microcarcinoma by central neck dissection.
Zhang L; Liu Z; Liu Y; Gao W; Zheng C
World J Surg Oncol; 2015 Apr; 13():138. PubMed ID: 25889385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
